Drugs for Rheumatoid Arthritis
May 1, 2012 (Issue: 117)
Disease-modifying anti-rheumatic drugs (DMARDs)
are now used early in the treatment of rheumatoid
arthritis (RA) to achieve clinical remission, prevent
irreversible damage to joints, and minimize toxicity
associated with nonsteroidal...more
1. JA Singh et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64:625.
2. SLWestlake et al.The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2010; 49:295.
3. A Golding et al. Rheumatoid arthritis and reproduction. Rheum Dis Clin North Am 2007; 33:319.
4. N Alcorn et al. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32:1123.
5. F Vroom et al. Disease modifying antirheumatic drugs in pregnancy: current status and implications for the future. Drug Saf 2006; 29:845.
6. YF Chen et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:iii.
7. Golimumab (Simponi) for inflammatory arthritis. Med Lett Drugs Ther 2009; 51:55.
8. Certolizumab (Cimzia) for Crohn’s disease. Med Lett Drugs Ther 2008; 50:81.
9. JD Carter et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36:635.
10. Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:34.
11. SB Cohen et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double- blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793.
12. Abatacept (Orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48:17.
13. MC Genovese et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011; 63:2854.
14. Tocilizumab (Actemra) for rheumatoid arthritis. Med Lett Drugs Ther 2010; 52:47.
15. RF van Vollenhover et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012. Epub ahead of print.
16. B Kuriya et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69:1298.
17. YH Lee et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28:553.
18. KE Donahue et al. Systemic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.
19. Adult immunization. Treat Guidel Med Lett 2011; 9:75.
20. Drugs for pain. Treat Guidel Med Lett 2010; 8:25.
21. Diclofenac gel for osteoarthritis. Med Lett Drugs Ther 2008; 50:31.
22. PL McCormack. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 2011; 71:2457.
23. Primary prevention of ulcers in patients taking aspirin or NSAIDs. Med Lett Drugs Ther 2010; 52:17.
24. Naproxen/esomeprazole (Vimovo). Med Lett Drugs Ther 2010; 52:74.
25. A fixed-dose combination of ibuprofen and famotidine (Duexis). Med Lett Drugs Ther 2011; 53:85.
26. ME Farkouh and BP Greenberg. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103:1227.
27. P McGettigan and D Henry. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8:e1001098.
28. WB White et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99:91.
29. MF Bakker et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 2012; 156:329.
30. E Dernis et al. Use of glucocorticoids in rheumatoid arthritis - practical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine 2010; 77:451.
31. Drugs for postmenopausal osteoporosis. Treat Guidel Med Lett 2011; 9:67.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
